glp 1 postmenopausal women GLP-1 Weight Loss in Menopause: How HRT Amplifies Results GLP-1 Microdosing During Menopause: Is

Embla coaches work with members to: Set achievable goals and build consistency in daily behaviors Identify and defuse unhelpful thoughts and food-related coping patterns Prepare for plateaus and relapses and navigate through them Develop the confidence and skills to maintain weight loss for life Real-world outcomes: what employers should expect Employers implementing coaching-first models like Embla's can expect: Improved medication efficiency members use lower doses and taper sooner, which reduces total drug spend Higher engagement and adherence weekly video coaching drives strong retention and satisfaction Lower long-term costs less reliance on high-cost GLP-1s, fewer comorbidities, and healthier employee populations Transparent reporting dashboards that track individual and population-level outcomes, including weight loss, medication usage, and program ROI We've worked with employers where 8085% of members stay engaged for 6+ months, and more than half continue engaging after medication has ended because they've built a trusted relationship with their coach

Access with U.S.-licensed clinicians via telehealth Free Eligibility Assessment GLP-1 and GLP-1 + GIP treatment options Free tracked medication delivery 24/7 Support, Unlimited check-ins TrimRx offers the simplest way to start your GLP-1 weight loss journey without insurance

The technology rapidly progressed with several types of co-agonists forging ahead in clinical trials including GIP/GLP-1 receptor dual agonists with one of the most notable being tirzepatide [8,9]

These medications work by reducing appetite, increasing feelings of fullness, and slowing digestion, which helps decrease calorie intake and promotes sustainable weight loss

One such study by McClean and colleagues [61] observed that liraglutide can cross the blood-brain barrier in substantial amounts and can prevent deficits in the water maze task performance and object recognition in AD model mice